UK lab-in-a-bead co attracts £2m-plus investment:
This article was originally published in Clinica
Cardiff, UK-based start-up Q Chip, which is developing its ReaX portfolio of customised bead-based, ready-assembled reagents for simplified and accurate DNA testing, has clinched over £2m ($4m) in it latest fundraising round. The proceeds will be used to accelerate product development, sale and marketing activities and expand the company's production capacity. The financing came from new investors Forum des Entrepreneurs (Geneva, Switzerland), the Sustainable Technology Fund and Finance Wales (both UK-based). Existing shareholders E-Synergy's Early Growth Fund, Biofusion and Jon Moulton (managing partner of private equity firm Alchemy Partners) also participated in the round.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.